AlanSubie4Life
Efficiency Obsessed Member
This is from the discussion conclusions in a recent paper from a well-regarded researcher in South Africa. The paper itself is fairly technical (link below):
“While higher titres of neutralizing antibodies are common in hospitalized individuals, however most SARS- CoV-2 infected people [with no or mild/moderate symptoms] develop moderate neutralization titres. >>>>Therefore, the data herein suggest that most individuals infected with previous SARS-CoV-2 lineages will have minimal or no detectable neutralization activity against 501Y.V2 [AKA B.1.351 AKA South African variant]. <<<<”
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
I guess that is somewhat promising. Maybe the vaccines will work well enough on these variants to keep them from spreading, with much higher antibody levels present after vaccination than there is after a minor infection.
I came across this long but useful Twitter thread tonight. It makes me feel a little sad. But at least the vaccines seem to work against B.1.1.7, which is the only one that is *confirmed* to be more contagious, at the moment. Other variants may be, but I haven’t seen the data.
Summary: With what we currently understand...Expect B.1.1.7 to dominate in areas of the US that have not been hit hard yet (assuming vaccination is too slow). And for the P.1 Brazil and B.1.351 South African strains expect that they may only flourish where there is a lot of population immunity (think the Dakotas).
https://twitter.com/k_g_andersen/status/1355689990487896065?s=21
What makes me sad is the speculation about other reasons these strains may be escaping B-cell mediated immunity. If there is some other reason, other than a key epitope change, that it is evading immunity, that is bad.
An excerpt:
We’ll know more in the coming weeks, as there is detailed study of these strains and how they interact with induced immunity.
What seems the most important is the effect of vaccination and (less important) prior infection on the risk of severe disease upon reinfection (and the effect of vaccination on transmissibility of the variant during any illness). Not a lot of detail on that yet.
Last edited: